The U.S. Food and Drug Administration cleared ArteraAI Breast, the first and only FDA-cleared digital pathology-based AI test for breast cancer risk stratification.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA clears ArteraAI Breast for breast cancer risk stratification
AI Cancer Test Technology type
12,000 Patients Patient cohort
95% Survival rate
FDA Clearance
6 clinical trials
68% low-risk patients